CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, has signed a contract for distribution of its Vergenix Flowable Gel product covering Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan, it was reported on Monday.
The firm stated that it has received its first order for a fee running into hundreds of thousands of US dollars. According to the terms of the deal, CollPlant will deliver a part of the order immediately and the remainder over the next six months, with the contract covering a five-year period.
The product is based on the firm's rhCollagen technology aimed at treating acute and chronic hard-to-heal wounds including diabetic ulcers, pressure sores, surgical cuts and trauma wounds.
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
10XREVIV Launch Announced in Abu Dhabi Through Partnership Between 10X Health, REVIV Global and M42
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Novo Nordisk to acquire Akero Therapeutics in USD5.2bn deal to strengthen MASH pipeline
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe